Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis advances strategy ...
--Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announc...
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...
-Brain diagnostics innovator BrainScope announced a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s ...
-Zivian Health, Inc., the first and only healthcare SaaS platform that empowers compliant collaborations between nurse practitioners (NP) and physician ass...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
Highlights: Reported revenue of $1.67 billion declined 2.7% year-over-year, and decreased 2.3% on a core(1) basis. GAAP net income of $111 millio...
ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...
Leede Jones Gable Inc. acted as underwriter and bookrunner (the "Underwriter") in accordance with the terms of an underwriting agreement between the Compan...
Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a curre...
Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organ...
Recorded Q2’23 consolidated revenue of KRW 866.2 billion Recorded Q2’23 consolidated operating profit of KRW 253.4 billion&nbs...
Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the s...
“The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as part...
© 2025 Biopharma Boardroom. All Rights Reserved.
